Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1937]

Lenalidomide versus thalidomide in myeloma

Prof Keith Stewart - Mayo Clinic, Scottsdale, USA

Lenalidomide versus thalidomide in myeloma ( Prof Keith Stewart - Mayo Clinic, Scottsdale, USA )

Comment: Advances in haematological cancer presented at EHA 2014

Prof Pieter Sonneveld - University Hospital Rotterdam, Netherlands

Comment: Advances in haematological cancer presented at EHA 2014 ( Prof Pieter Sonneveld - University Hospital Rotterdam, Netherlands )

Advances in mantle cell lymphoma: Expert discussion

Prof Simon Rule and Prof Franco Cavalli

Advances in mantle cell lymphoma: Expert discussion ( Prof Simon Rule and Prof Franco Cavalli )

Advances in chronic lymphocytic leukaemia: Expert panel discussion

Prof Peter Hillmen; Prof John Gribben; Prof Stephen Mulligan

Advances in chronic lymphocytic leukaemia: Expert panel discussion ( Prof Peter Hillmen; Prof John Gribben; Prof Stephen Mulligan )

Genetically modified T cells fight haematological cancer

Dr Roman Galetto - Cellectis Therapeutics, Paris, France

Genetically modified T cells fight haematological cancer ( Dr Roman Galetto - Cellectis Therapeutics, Paris, France )

Pivotal ruxolitinib data shows promise for patients with PV

Prof Alessandro Vannucchi - University of Florence, Florence, Italy

Pivotal ruxolitinib data shows promise for patients with PV ( Prof Alessandro Vannucchi - University of Florence, Florence, Italy )

Novel Bcl-2 specific inhibitor updated results confirm substantial activity and...

Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia

Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL ( Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia )

Does the use of generics of imatinib for chronic myeloid leukaemia jeopardise...

Dr Zafer Başlar - Istanbul University, Istanbul, Turkey

Does the use of generics of imatinib for chronic myeloid leukaemia jeopardise patient safety? ( Dr Zafer Başlar - Istanbul University, Istanbul, Turkey )

Blinatumomab shown to be beneficial in relapsed/refractory B-precursor acute...

Prof Max Topp - Würzburg University Hospital, Würzburg, Germany

$Blinatumomab shown to be beneficial in relapsed/refractory B-precursor acute lymphoblastic leukaemia ( Prof Max Topp - Würzburg University Hospital, Würzburg, Germany )$

ASCO 2014 roundup

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

ASCO 2014 roundup ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )

Mantle cell lymphoma: A review of data and expert opinion from ASCO 2014

Prof Franco Cavalli, Prof Gordon McVie

Mantle cell lymphoma: A review of data and expert opinion from ASCO 2014 ( Prof Franco Cavalli, Prof Gordon McVie )

Ibrutinib significantly delays disease progression and extends survival in...

Dr John Byrd - The Ohio State University, Columbus, USA

Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL ( Dr John Byrd - The Ohio State University, Columbus, USA )

More from ecancer